Alaunos Therapeutics, INC. 8-K Filing
Ticker: TCRT · Form: 8-K · Filed: Dec 23, 2025 · CIK: 1107421
| Field | Detail |
|---|---|
| Company | Alaunos Therapeutics, INC. (TCRT) |
| Form Type | 8-K |
| Filed Date | Dec 23, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $285,055, $142,528, $28,506 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Alaunos Therapeutics, INC. (ticker: TCRT) to the SEC on Dec 23, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ch registered Common Stock, par value $0.001 per share TCRT The Nasdaq Stock Mar); $285,055 (ny agreed to pay MD Anderson a total of $285,055 in full satisfaction of the outstanding); $142,528 (, payable in installments as follows: $142,528 on or before December 30, 2025; $28,5); $28,506 (2,528 on or before December 30, 2025; $28,506on or before January 30, 2026; $28,506).
How long is this filing?
Alaunos Therapeutics, INC.'s 8-K filing is 2 pages with approximately 583 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 583 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2025-12-23 17:18:31
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share TCRT The Nasdaq Stock Mar
- $285,055 — ny agreed to pay MD Anderson a total of $285,055 in full satisfaction of the outstanding
- $142,528 — , payable in installments as follows: $142,528 on or before December 30, 2025; $28,5
- $28,506 — 2,528 on or before December 30, 2025; $28,506on or before January 30, 2026; $28,506
Filing Documents
- tcrt-20251217.htm (8-K) — 61KB
- tcrt-ex10_1.htm (EX-10.1) — 45KB
- 0001193125-25-331147.txt ( ) — 214KB
- tcrt-20251217.xsd (EX-101.SCH) — 28KB
- tcrt-20251217_htm.xml (XML) — 5KB
01 - Entry into a Material Definitive Agreement
Item 1.01 - Entry into a Material Definitive Agreement On December 17, 2025, Alaunos Therapeutics, Inc. (the "Company") entered into a Settlement and Release Agreement (the "Settlement Agreement") with The University of Texas M.D. Anderson Cancer Center ("MD Anderson") resolving all disputes related to unpaid invoices under the 2019 Research and Development Agreement. Under the Settlement Agreement, the Company agreed to pay MD Anderson a total of $285,055 in full satisfaction of the outstanding invoices, payable in installments as follows: $142,528 on or before December 30, 2025; $28,506on or before January 30, 2026; $28,506 on or before February 28, 2026; $28,506 on or before March 30, 2026; $28,506 on or before April 30, 2026; and $28,506 on or before May 30, 2026. The Settlement Agreement includes mutual general releases of claims arising from or relating to the unpaid invoices, with customary exceptions including for breach of the Settlement Agreement itself and certain ongoing matters such as Protocol 2006-0676. The foregoing description of the Settlement Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Settlement Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
01 – Financial Statements and Exhibits
Item 9.01 – Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 10.1 Settlement Agreement, dated December 17, 2025
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Alaunos Therapeutics, Inc. Date: December 23, 2025 By: /s/ Holger Weis Name: Holger Weis Title: Chief Executive Officer